Head-To-Head Contrast: Digirad (NASDAQ:DRAD) & BioSig Technologies (NASDAQ:BSGM)

Digirad (NASDAQ:DRAD) and BioSig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.

Profitability

This table compares Digirad and BioSig Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Digirad -5.81% -10.97% -5.06%
BioSig Technologies N/A -301.90% -247.03%

Institutional & Insider Ownership

38.2% of Digirad shares are held by institutional investors. Comparatively, 11.9% of BioSig Technologies shares are held by institutional investors. 7.3% of Digirad shares are held by insiders. Comparatively, 19.0% of BioSig Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Digirad and BioSig Technologies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Digirad 0 0 0 0 N/A
BioSig Technologies 0 0 2 0 3.00

BioSig Technologies has a consensus price target of $12.50, suggesting a potential upside of 79.08%. Given BioSig Technologies’ higher possible upside, analysts clearly believe BioSig Technologies is more favorable than Digirad.

Risk & Volatility

Digirad has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Comparatively, BioSig Technologies has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Earnings & Valuation

This table compares Digirad and BioSig Technologies’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Digirad $104.18 million 0.08 $740,000.00 N/A N/A
BioSig Technologies N/A N/A -$17.25 million N/A N/A

Digirad has higher revenue and earnings than BioSig Technologies.

Summary

Digirad beats BioSig Technologies on 6 of the 10 factors compared between the two stocks.

About Digirad

Digirad Corporation provides healthcare solutions in the United States and internationally. It operates through three segments: Diagnostic Services, Mobile Healthcare, and Diagnostic Imaging. The Diagnostic Services segment provides nuclear and ultrasound imaging services to physicians who perform nuclear imaging, echocardiography, vascular or general ultrasound tests, imaging systems, radiopharmaceuticals, and licensing services. The Mobile Healthcare segment offers contract diagnostic imaging services, including computerized tomography (CT), magnetic resonance imaging, positron emission tomography (PET), PET/CT, and nuclear medicine and healthcare services to hospitals, integrated delivery networks, and federal institutions on a long-term contract basis, as well as provisional services to institutions that are in transition. The Diagnostic Imaging segment develops and sells gamma camera imaging systems, such as nuclear cardiac imaging systems and general purpose nuclear imaging systems to physician offices and hospitals; and offers camera maintenance services. Digirad Corporation was founded in 1985 and is headquartered in Suwanee, Georgia.

About BioSig Technologies

BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Los Angeles, California.

Receive News & Ratings for Digirad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit